MapLight Therapeutics, Inc. (MPLT) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 15, 2026
Current Price
$28.73
Price Target
$33.80
Target Range
$28.00 — $45.00
Analyst Rating
—
Forward P/E—
Trailing P/E-15.4x
Forward PEG—
Implied Growth-73.4%
Median Target$32.00
Analyst Spread50.3%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$28
-2.5%
Consensus
$34
+17.6%
Bull Case
$45
+56.6%
MPLT Price Target Analysis
Updated May 15, 2026As of May 15, 2026, MapLight Therapeutics, Inc. (MPLT) has a Wall Street consensus price target of $33.80, based on estimates from 0 covering analysts. With the stock currently trading at $28.73, this represents a potential upside of +17.6%. The company has a market capitalization of $1.30B.
Analyst price targets range from a low of $28.00 to a high of $45.00, representing a 50% spread in expectations. The median target of $32.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, MPLT trades at a trailing P/E of -15.4x. Analysts expect EPS to grow -73.4% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+33.2%
Avg Forward P/E24.3x
Peers with Coverage7 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ACNBACNB Corporation | $539M | $52.03 | $58.00 | +11.5% | Buy | 9.6x | 2 |
 PTGXProtagonist Therapeutics, Inc. | $6.6B | $102.18 | $115.40 | +12.9% | Buy | 25.7x | 26 |
 TERNTerns Pharmaceuticals, Inc. | $4.8B | $52.95 | $55.56 | +4.9% | Buy | — | 16 |
 ACLXArcellx, Inc. | $6.7B | $115.07 | $112.45 | -2.3% | Hold | — | 18 |
 NRXPNRx Pharmaceuticals, Inc. | $91M | $3.28 | — | — | — | — | — |
 SAVACassava Sciences, Inc. | $94M | $1.96 | — | — | Buy | — | 12 |
 ACADACADIA Pharmaceuticals Inc. | $3.7B | $21.40 | $34.78 | +62.5% | Buy | 54.9x | 37 |
 INVAInnoviva, Inc. | $1.6B | $21.97 | $40.00 | +82.1% | Buy | 7.0x | 10 |
 PRAXPraxis Precision Medicines, Inc. | $9.9B | $342.58 | $549.80 | +60.5% | Buy | — | 16 |
 NRXSNeurAxis, Inc. | $97M | $7.87 | — | — | — | — | — |
Upside Potential Comparison
INVAACADPRAXPTGXACNBTERNACLXSee MPLT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MPLT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare with Peers
Compare business quality, growth, and profitability against top sector peers.
Start ComparisonMPLT — Frequently Asked Questions
Quick answers to the most common questions about buying MPLT stock.
What is the MPLT stock price target for 2026?
MapLight Therapeutics, Inc. (MPLT) has a consensus 12-month price target of $33.8, implying 17.6% upside from $28.73. The 0 analysts covering MPLT see moderate appreciation potential.
Is MPLT a buy, sell, or hold?
MPLT has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $33.8 implies 17.6% upside from current levels.
Is MPLT stock overvalued or undervalued?
MPLT's current price is $28.73 with a consensus target of $33.8 (17.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can MPLT stock go?
The most bullish Wall Street analyst has a price target of $45 for MPLT, while the most conservative target is $28. The consensus of $33.8 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover MPLT stock?
MPLT is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the MPLT stock forecast?
The 12-month MPLT stock forecast based on 0 Wall Street analysts shows a consensus price target of $33.8, with estimates ranging from $28 (bear case) to $45 (bull case). The median consensus rating is "N/A".
Should I buy MPLT stock?
Wall Street analysts are optimistic on MPLT, with a "N/A" consensus rating and $33.8 price target (17.6% upside). 0 of 0 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do MPLT price targets vary so much?
MPLT analyst price targets range from $28 to $45, a 50% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $33.8 consensus represents the middle ground.